Seres Therapeutics to Initiate New SER-109 Clinical Study
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- Abbott plans to spin off its nutrition unit as a standalone public company
- AMD shares fall amid AI chip sector selloff
- Alphabet shares drop ahead of earnings next week
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- JetBlue shares fall amid American results, fuel cost concerns
Seres Therapeutics (MCRB) Tops Q4 EPS by 9c
March 16, 2017 7:25 AM EDTSeres Therapeutics (NASDAQ: MCRB) reported Q4 EPS of ($0.63), $0.09 better than the analyst estimate of ($0.72). Revenue for the quarter came in at $3 million versus the consensus estimate of $2.85 million.
For earnings history and earnings-related data on Seres Therapeutics (MCRB) click here.
... More


